At argenx, we are pioneering innovation in autoimmune disease research through advanced immunology science and collaboration with patients, caregivers, and advocacy partners.
Explore the studies below to learn more about each clinical trial, including eligibility criteria, study details, and participation opportunities.
- Antibody-Mediated Rejection
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Congenital Myasthenic Syndromes (CMS)
- Delayed Graft Function (DGF)
- Graves' Disease
- Immune Thrombocytopenia (ITP)
- Multifocal Motor Neuropathy (MMN)
- Myasthenia Gravis (MG)
- Myositis (IMNM, ASyS, DM)
- Primary Sjogren’s Disease (pSjD)
- Spinal Muscular Atrophy (SMA)
- Systemic Sclerosis
Program: Efgartigimod
A Phase 2, Multicenter, Randomized, Double-Blinded, Placebo-Controlled study, to Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC Administered by a Prefilled Syringe in Kidney Transplant Recipients with Antibody-Mediated Rejection
Emvigorate
Program: Empasiprubart
A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy.
Emnergize
Program: Empasiprubart
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Empasiprubart IV in Adults With Chronic Inflammatory Demyelinating Polyneuropathy.
Emlight
Program: Empasiprubart
An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy.
CMS Natural History Study
Program: Adimanebart
Multicenter, Multinational, Natural History Study in Participants With Congenital Myasthenic Syndromes Due to Mutations in DOK7, MUSK, AGRN, or LRP4.
CMS Phase 1b – ARGX-119-2302
Program: Adimanebart
A Phase 1b, Double-Blinded, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Efficacy of ARGX-119 in Adult Participants with DOK7-Congenital Myasthenic Syndromes.
Varvara
Program: Empasiprubart
Phase 2, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Assess the Safety, Efficacy, and Tolerability of ARGX-117 in Improving Allograft Function in Recipients of a Deceased Donor Renal Allograft at Risk for Delayed Graft Function.
Vitalithy
Program: Efgartigimod
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyroid Drugs
Advance Next (ITP)
Program: Efgartigimod
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Adult Participants with Primary Immune Thrombocytopenia.
Advance Jr.
Program: Efgartigimod
A Multicenter, Randomized, Double-blinded, Parallel-Arm, Placebo-Controlled, Pharmacokinetic and Pharmacodynamic Study Followed by an Open-Label Arm to Evaluate Efgartigimod IV in Pediatric Participants From 12 Years to Less Than 18 Years of Age With Chronic ITP
Empassion
Program: Empasiprubart
A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Empasiprubart Versus Intravenous Immunoglobulin in Adults with Multifocal Motor Neuropathy.
ARDA
Program: Empasiprubart
A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy.
iMMersioN
Program: Empasiprubart
A Multicenter Prospective Longitudinal Study of Clinical Outcomes, Disease Course, Health-Related Quality of Life, and Health Care Resource Utilization in Adult Patients With Multifocal Motor Neuropathy.
EmpaSound
Program: Empasiprubart
An Open-Label, Single-Arm, Phase 1b Study to Evaluate the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor Neuropathy.
Adapt Seron
Program: Efgartigimod
Phase 3 trial of IV efgartigimod for the treatment of AChR- Generalized Myasthenia Gravis (gMG).
Adapt Oculus
Program: Efgartigimod
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Design Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants with Ocular Myasthenia Gravis.
Adapt Jr.
Program: Efgartigimod
Open-label Uncontrolled Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod in Children From 2 to Less Than 18 Years of Age with Generalized Myasthenia Gravis.
Adapt Jr. Sc
Program: Efgartigimod
Open-label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod PH20 SC in Participants From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis.
Adapt Forward
Program: Combination
A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis.
Navyvgate
Program: Efgartigimod
Post-approval Non-Interventional Safety Study Observational, non-interventional, post-approval safety study (Ph4) in adult patients who have been diagnosed with generalized myasthenia gravis (gMG).
Post-approval Non-interventional Safety Study
Program: Efgartigimod
A Worldwide Pregnancy Safety Study (Ph4) to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy And/Or Breastfeeding.
Alkivia
Program: Efgartigimod
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy.
Unity
Program: Efgartigimod
A Phase 3 Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial with Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjögren's Disease.
Sparkle
Program: Adimanebart
A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy (Sparkle).
Esscape
Program: Efgartigimod
A Randomized, Double-Blinded, Placebo-Controlled, Phase 2, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Adult Participants With Systemic Sclerosis.
Shamrock
Program: Efgartigimod
A Phase 2, Multicenter, Randomized, Double-Blinded, Placebo-Controlled study, to Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC Administered by a Prefilled Syringe in Kidney Transplant Recipients with Antibody-Mediated Rejection
Emvigorate
Program: Empasiprubart
A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy.
Emnergize
Program: Empasiprubart
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Empasiprubart IV in Adults With Chronic Inflammatory Demyelinating Polyneuropathy.
Emlight
Program: Empasiprubart
An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy.
CMS Natural History Study
Program: Adimanebart
Multicenter, Multinational, Natural History Study in Participants With Congenital Myasthenic Syndromes Due to Mutations in DOK7, MUSK, AGRN, or LRP4.
CMS Phase 1b – ARGX-119-2302
Program: Adimanebart
A Phase 1b, Double-Blinded, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Efficacy of ARGX-119 in Adult Participants with DOK7-Congenital Myasthenic Syndromes.
Varvara
Program: Empasiprubart
Phase 2, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Assess the Safety, Efficacy, and Tolerability of ARGX-117 in Improving Allograft Function in Recipients of a Deceased Donor Renal Allograft at Risk for Delayed Graft Function.
Vitalithy
Program: Efgartigimod
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyroid Drugs.
Advance Next (ITP)
Program: Efgartigimod
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Adult Participants with Primary Immune Thrombocytopenia.
Advance Jr.
Program: Efgartigimod
A Multicenter, Randomized, Double-blinded, Parallel-Arm, Placebo-Controlled, Pharmacokinetic and Pharmacodynamic Study Followed by an Open-Label Arm to Evaluate Efgartigimod IV in Pediatric Participants From 12 Years to Less Than 18 Years of Age With Chronic ITP
Empassion
Program: Empasiprubart
A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Empasiprubart Versus Intravenous Immunoglobulin in Adults with Multifocal Motor Neuropathy.
ARDA
Program: Empasiprubart
A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy.
iMMersioN
Program: Empasiprubart
A Multicenter Prospective Longitudinal Study of Clinical Outcomes, Disease Course, Health-Related Quality of Life, and Health Care Resource Utilization in Adult Patients With Multifocal Motor Neuropathy.
EmpaSound
Program: Empasiprubart
An Open-Label, Single-Arm, Phase 1b Study to Evaluate the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor Neuropathy.
Adapt Seron
Program: Efgartigimod
Phase 3 trial of IV efgartigimod for the treatment of AChR- Generalized Myasthenia Gravis (gMG).
Adapt Oculus
Program: Efgartigimod
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Design Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants with Ocular Myasthenia Gravis.
Adapt Jr.
Program: Efgartigimod
Open-label Uncontrolled Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod in Children From 2 to Less Than 18 Years of Age with Generalized Myasthenia Gravis.
Adapt Jr. Sc
Program: Efgartigimod
Open-label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod PH20 SC in Participants From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis.
Adapt Forward
Program: Combination
A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis.
Navyvgate
Program: Efgartigimod
Post-approval Non-Interventional Safety Study Observational, non-interventional, post-approval safety study (Ph4) in adult patients who have been diagnosed with generalized myasthenia gravis (gMG).
Post-approval Non-interventional Safety Study
Program: Efgartigimod
A Worldwide Pregnancy Safety Study (Ph4) to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy And/Or Breastfeeding.
Alkivia
Program: Efgartigimod
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy.
Unity
Program: Efgartigimod
A Phase 3 Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial with Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjögren's Disease.
Sparkle
Program: Adimanebart
A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy (Sparkle).
Esscape
Program: Efgartigimod
A Randomized, Double-Blinded, Placebo-Controlled, Phase 2, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Adult Participants With Systemic Sclerosis.
Access to Investigational Medicines
Our approach is guided by patient need, physician recommendation, and responsible access to investigational therapies where no suitable treatment alternatives are available.
Expanded Access
Expanded Access, sometimes called “compassionate use,” may allow eligible patients with serious or life-threatening conditions to access an investigational medicine outside of a clinical trial before it is approved by regulatory authorities.
argenx supports Expanded Access Programs (EAPs) as a way to help eligible patients gain access to investigational medicines before regulatory approval, when appropriate and permitted by local regulations.
Post-trial Access
Post-Trial Access refers to continued access to an investigational medicine for eligible participants after they complete a clinical trial, when continued treatment may be considered appropriate.
argenx is committed to supporting patients throughout the clinical research journey, including through Post-Trial Access (PTA) programs for eligible participants following completion of a clinical trial.
